

SERVING THE NEEDS OF THE DIVERSE POPULATION



ASCP
AMERICAN SOCIETY OF
CLINICAL PSYCHOPHARMACOLOGY

MAY 29 – JUNE 2, 2017 | LOEWS MIAMI BEACH HOTEL | MIAMI, FLORIDA

2017 ANNUAL MEETING

Continuing Education Credit Information for the 2017 ASCP Annual Meeting

This meeting is jointly sponsored by the American Society of Clinical Psychopharmacology and AMEDCO.



Continuing Education Credits are available for physicians, pharmacists, and psychologists. Applications for credit must be completed online with the meeting evaluation survey. There is a \$40.00 administrative fee for self-assessment MOC/CME/CE applications. It is the policy of the ASCP to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. The evaluation will be available online at www.ASCPMeeting.org during and after the meeting. To review the learning objectives and presenter disclosures for the Annual Meeting, please visit www.ASCPMeeting.org.

The 2017 ASCP Annual Meeting designates this live meeting as follows: (sessions and hours on second page)

Monday, May 29th – Latin America Symposium – 3.75 CME Hours/CE Hours

Tuesday, May 30 – Friday, June 2 – All sessions – 20 CME Hours/CE Hours

Combined Satellite Symposium and all sessions Monday, May 29 – Friday, June 2 – up to 23.75 CME Hours/CE Hours

The American Board of Psychiatry and Neurology has reviewed the Annual Meeting and has approved this program as part of a comprehensive self-assessment program, which is mandated by the ABMS as a necessary component of Maintenance of Certification.

Accreditation Statements

Physicians:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Amedco and the American Society of Clinical Psychopharmacology (ASCP). Amedco is accredited by the ACCME to provide continuing medical education for physicians.

Amedco designates this live activity for a maximum of 23.75 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants must complete an evaluation form in order to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available.

Psychologists:

This course is co-sponsored by Amedco and American Society of Clinical Psychopharmacology (ASCP). Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists. Amedco maintains responsibility for this program and its content. 23.75 hours. **Partial credit will not be awarded for APA credits. Participants must attend the entire meeting.**

Pharmacists:

Amedco is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Successful completion of this program qualifies for up to 23.75 contact hours. UANs: 0453-9999-17-171-L04-P(K) – 0453-9999-17-214-L04-P(K). **In order to receive full credit, registrants must arrive no later than 10 minutes after the start of the meeting and must attend the entire meeting.**

ASCP Annual Meeting Approved Educational Credit Hours

Monday, May 29 th	Credits	
12:00pm - 4:00pm	3.75	Latin American Symposia
Tuesday, May 30th		
9:00am – 10:30am	1.5	<u>Panel:</u> <i>Implementing Measurement-based Care in Clinical Practice</i>
	1.5	<u>Panel:</u> <i>Inflammation and Obesity in Depression: Neurobiological Mechanisms and ...</i>
	1*	<u>Panel:</u> <i>The Role of Modulators of the Opioid System in the Treatment of Neuropsychiatric Illnesses</i>
	1.5	<u>Panel:</u> <i>Pharmacotherapy and Psychosocial Treatment in First Episode Psychosis Studies...</i>
10:45am – 12:15pm	1.5	<u>Panel:</u> <i>Model-based Approaches to Assist Clinical Development of Psychiatric Products Development...</i>
	1.25*	<u>Panel:</u> <i>The Development.... A Review of Initiatives by the FDA, NIH, and the Alcohol Clinical Trials Initiative (ACTIVE)</i>
	1.5	<u>Panel:</u> <i>Targeting Treatment Needs in Women's Mental Health</i>
	1.5	<u>Panel:</u> <i>Development of Antidepressants with Novel Mechanisms of Action</i>
1:15pm – 1:45pm	.5	NIH Diversity Supplement Program
2:00pm – 4:00pm	No Credit	Pharmaceutical Pipelines
4:15pm – 5:30pm	1.25	<u>IRR:</u> <i>Advances in Schizophrenia Treatment and Assessment</i>
	1.25	<u>IRR:</u> <i>Focus on Neurocognition, Neurodegeneration, and Alcohol Misuse</i>
	1.25	<u>IRR:</u> <i>Treatment Adherence to Atypical Antipsychotic Medications, Ketamine, and Screening...</i>
	1*	<u>IRR:</u> <i>Understanding and Optimizing Treatments for Special Populations...</i>
Wednesday, May 31st		
8:30am – 10:00am	1.5	Regulatory Plenary
10:15am – 11:15am	1	ASCP Lifetime Awardee Talk
11:15am – 1:00pm	No Credit	Poster Session I with Lunch
1:00pm – 2:30pm	1.5	<u>Panel:</u> <i>Optimizing Neuromodulatory and Pharmacologic Approaches...</i>
	1.5	<u>Panel:</u> <i>Medication or Psychotherapy as First-line Treatment for Posttraumatic Stress Disorder?</i>
	1.25*	<u>Panel:</u> <i>Impact of Abnormal Involuntary Movements Across Diverse Clinical Populations</i>
	1.5	<u>Panel:</u> <i>Regulatory and Methodological Considerations in the Evaluation of Drug Dependence...</i>
2:30pm – 3:30 pm	No Credit	FDA 101 Session
3:45pm – 5:45pm	2	<u>Workshop:</u> <i>Reducing Health Disparities by Promoting Functional and Life-satisfaction Assessments...</i>
	2	<u>Workshop:</u> <i>Tardive Dyskinesia: The Forgotten Adverse Event</i>
	2	<u>Workshop:</u> <i>Novel Applications of Ketamine</i>
	2	<u>Workshop:</u> <i>Hot Button Topics in Negotiation for Mid-Career Professionals in Psychopharmacology and Allied Fields</i>
Thursday, June 1st		
8:15am – 9:45am	1.5	<u>Keynote Plenary:</u> <i>Social Determinants of Mental Health; Patient Centered Approaches to Care/PPRNs</i>
10:00am – 12:30pm	2.5	Federal Agency Directors Plenary
12:30pm – 2:00pm	No Credit	Poster Session II with Lunch
2:00pm – 3:30pm	1.5	Updates Session
3:45pm – 5:45pm	2	<u>Workshop:</u> <i>Psychotropics and Pregnancy: Current Practice to Evidence Based Approaches</i>
	2	<u>Workshop:</u> <i>Rapid-acting Antidepressants: Perspective on Issues in Nonclinical and Clinical Development from the Division of Psychiatry Products (DPP), Food and Drug Administration</i>
	2	<u>Workshop:</u> <i>How to use the Model Psychopharmacology Curriculum in Various Teachings</i>
Friday, June 2nd		
8:30am – 10:00am	1.5	<u>Panel:</u> <i>Validly and Reliably Measuring Functional Performance in Dementia Patients across Countries...</i>
	1.5	<u>Panel:</u> <i>Neuromodulation with Transcranial Near-infrared Light: Controlled Evidence</i>
	1.5	<u>Panel:</u> <i>Suicidal Behavior in the Clinical Setting: Relationship Between ADHD, Depression...</i>
	1.5	<u>Panel:</u> <i>New Technologies for Reducing Placebo Response and Improving Signal Detection...</i>
10:15am – 11:45am	1.5	Regulatory Wrap-Up Plenary

*Hours noted exclude portion of sessions that are not eligible for continuing education.